Pharmaceutical Supply – Paxlovid (Nirmatrelvir and Ritonavir Tablets)

The contract involves the supply and delivery of 50 boxes of Paxlovid, containing Nirmatrelvir 300 mg and Ritonavir 100 mg tablets, for a total of 4,500 tablets, classified as a commercial off-the-shelf pharmaceutical product. The requirement is solicited under the Department of Defense through the Medical Supply Chain Pharm FSA, with the place of performance specified as Williamsburg, Virginia, 23185. The solicitation is structured as a subcontract and was posted on July 29, 2026, with responses due by August 4, 2026, indicating a competitive but time-sensitive procurement process. The NAICS code 325412 corresponds to pharmaceutical and biological product manufacturing, underscoring the regulated nature of the product and the need for compliance with industry standards for distribution and handling. The contract does not include any set-aside provisions, meaning it is open to all qualified suppliers without restriction based on business size or ownership category. Although no point of contact is listed, the official solicitation can be accessed through the DIBBS portal using the provided link. All deliveries must meet stringent pharmaceutical handling and validation requirements to ensure product integrity, and the supplier must guarantee adherence to current Good Manufacturing Practices and regulatory compliance throughout the supply chain. Timely delivery to the designated location is critical, as the product is intended for medical use within the DOD health system, and any failure to meet specifications or deadlines could impact patient care.